CD19 and acute lymphoblastic leukemia: Recent Phase I clinical trials with CD19-targeted, 2nd generation of chimeric antigen receptor (CAR) T cells containing 4-1BB signaling domain have shown a complete remission (CR) rate of >86% in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [3].